RBC Capital analyst Craig Wong-Pan downgrades ResMed (NYSE:RMD) from Outperform to Sector Perform and raises the price target from $246 to $252.
ClearPoint Neuro Congratulates Its Partner AviadoBio On First Patient Treated In Its ASPIRE-FTD Clinical Trial Evaluating AVB-101 For Frontotemporal Dementia With GRN Mutations
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its
